Monoclonal antibodies (mAbs) targeting programmed cell death‐1 (PD‐1), programmed cell death ligand‐1 (PD‐L1), and cytotoxic T‐lymphocyte‐associated antigen‐4 (CTLA‐4) immune checkpoints have been approved for the treatment of a variety of cancers, including NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.